Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

Inclusion Criteria:

* Diagnosis of chronic lymphocytic leukemia:
* Previously treated patients of any age with a diagnosis of CLL with documented residual disease following therapy, but not meeting an indication for treatment based on current guidelines
* At least 2 months following previous CLL directed therapy
* ECOG performance status of less than or equal to 2 at study entry
* Laboratory test results within these ranges:

  * Platelet count greater than or equal to 50 x 109/L
  * CrCl \>.60 ml/min
  * Total bilirubin less than or equal to 1.5 mg/dL
  * AST (SGOT) and ALT (SGPT) less than or equal to 2 x ULN
* Females of childbearing must adhere to strict guidelines and have negative pregnancy test prior to enrollment
* Understand and voluntarily sign an informed consent form.
* Age greater than or equal to 18 years at the time of signing the informed consent form.
* Able to adhere to the study visit schedule and other protocol requirements.
* Disease free of prior malignancies for greater than or equal to 2 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ" of the cervix or breast.
* All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®.
* Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin may use warfarin or low molecular weight heparin).

Exclusion Criteria:

* Known Hepatitis B Ag positive, Hepatitis C positive patients.
* Known HIV positive patients.
* Patients with uncontrolled Autoimmune Hemolytic Anemia (AIHA) or autoimmune thrombocytopenia (ITP)
* Patients with active fungal, bacterial, and/or viral infection
* Patients with known hypersensitivity to Revlimid or thalidomide
* Concurrent use of other anti-cancer agents or treatments
* Patients with history of deep venous thrombus or pulmonary embolism
* Patients who are at increased risk of thrombosis during treatment with Revlimid including those taking concurrent erythropoietin, darbepoetin or high-dose corticosteroids
* Inability to provide informed consent.
* Concurrent malignancy (excluding basal and squamous cell skin cancers).
* Pregnant or breast-feeding females. (Lactating females must agree not to breast feed while taking Revlimid).
* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
* Use of any other experimental drug or therapy within 28 days of baseline.
* The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
* Patients with a history of embolic events (e.g. TIA) from arrhythmia or peripheral arterial disease or of recent MI whether or not treated with anti-platelet drug.